Iain J. MacLeod

Iain J. MacLeod

Auto-generated profile, based on publicly available information

Iain J. MacLeod

Harvard T.H Chan School of Public Health, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2021 in Communications Biology
Verified
Journal Article
Open access
PDF file
IMIain J. MacLeod
Iain J. MacLeod
CRChristopher F. Rowley
Christopher F. Rowley
MEM. Essex
M. Essex
Sensitive and reproducible diagnostics are fundamental to containing the spread of existing and emerging pathogens. Despite the reliance of clinical virology on qPCR, technical challenges persist that compromise their reliability for sustainable epidemic containment as sequence instability in probe-binding regions produces false-negative results. We systematically violated canonical qPCR design principles to develop a Pan-Degenerate Amplification and Adaptation (PANDAA), a point mutation assay that mitigates the impact of sequence variation on probe-based qPCR performance. Using HIV-1 as a model system, we optimized and validated PANDAA to detect HIV drug resistance mutations (DRMs). Ultra-degenerate primers with 3’ termini overlapping the probe-binding site adapt the target through site-directed mutagenesis during qPCR to replace DRM-proximal sequence variation. PANDAA-quantified DRMs present at frequency ≥5% (2 h from nucleic acid to result) with a sensitivity and specificity of 96.9% and 97.5%, respectively. PANDAA is an innovative advancement with applicability to any pathogen where target-proximal genetic variability hinders diagnostic development.

7 May 2021 in AAS Open Research
Verified
Journal Article
Open access
PDF file
DMDorcas Maruapula
Dorcas Maruapula
IMIain J. MacLeod
Iain J. MacLeod
SMSikhulile Moyo
Sikhulile Moyo
RMRosemary Musonda
Rosemary Musonda
KSKaelo Seatla
Kaelo Seatla
CRChristopher F. Rowley
Christopher F. Rowley
Background:HIV-1 drug resistance poses a major threat to the success of antiretroviral therapy. The high costs of available HIV drug resistance assays prohibit their routine usage in resource-limited settings. Pan-degenerate amplification and adaptation (PANDAA), a focused genotyping approach based on quantitative PCR (qPCR), promises a fast and cost-effective way to detect HIV drug resistance mutations (HIVDRMs). Given the high cost of current genotyping methods, we sought to use PANDAA for screening key HIVDRMs in antiretroviral-naïve individuals at codons 103, 106 and 184 of the HIV-1 reverse transcriptase gene. Mutations selected at these positions have been shown to be the most common driver mutations in treatment failure. Methods:A total of 103 samples from antiretroviral-naïve individuals previously genotyped by Sanger population sequencing were used to assess and verify the performance of PANDAA. PANDAA samples were run on the ABI 7500 Sequence Detection System to genotype the K103N, V106M and M184V HIVDRMs. In addition, the cost per sample and reaction times were compared. Results:Sanger population sequencing and PANDAA detected K103N mutation in three (2.9%) out of 103 participants. There was no evidence of baseline V106M and M184V mutations observed in our study. To genotype the six HIVDRMs it costs approximately 40 USD using PANDAA, while the reagents cost per test for Sanger population sequencing is approximately 100 USD per sample. PANDAA was performed quicker compared to Sanger sequencing, 2 hours for PANDAA versus 15 hours for Sanger sequencing. Conclusion:The performance of PANDAA and Sanger population sequencing demonstrated complete concordance. PANDAA could improve patient management by providing quick and relatively cheap access to drug-resistance information.

28 September 2020 in AAS Open Research
Verified
Journal Article
Open access
PDF file
DMDorcas Maruapula
Dorcas Maruapula
IMIain J. MacLeod
Iain J. MacLeod
SMSikhulile Moyo
Sikhulile Moyo
RMRosemary Musonda
Rosemary Musonda
KSKaelo Seatla
Kaelo Seatla
CRChristopher F. Rowley
Christopher F. Rowley
Background:HIV-1 drug resistance poses a major threat to the success of antiretroviral therapy. The high costs of available HIV drug resistance assays prohibit their routine usage in resource-limited settings. Pan-degenerate amplification and adaptation (PANDAA), a focused genotyping approach based on quantitative PCR (qPCR), promises a fast and cost-effective way to detect HIV drug resistance mutations (HIVDRMs). Given the high cost of current genotyping methods, we sought to use PANDAA for screening key HIVDRMs in antiretroviral-naïve individuals at codons 103, 106 and 184 of the HIV-1 reverse transcriptase gene. Mutations selected at these positions have been shown to be the most common driver mutations in treatment failure. Methods:A total of 103 samples from antiretroviral-naïve individuals previously genotyped by Sanger population sequencing were used to assess and verify the performance of PANDAA. PANDAA samples were run on the ABI 7500 Sequence Detection System to genotype the K103N, V106M and M184V HIVDRMs. In addition, the cost per sample and reaction times were compared. Results:Sanger population sequencing and PANDAA detected K103N mutation in three (2.9%) out of 103 participants. There was no evidence of baseline V106M and M184V mutations observed in our study. To genotype the six HIVDRMs it costs approximately 40 USD using PANDAA, while the reagents cost per test for Sanger population sequencing is approximately 100 USD per sample. PANDAA was performed quicker compared to Sanger sequencing, 2 hours for PANDAA versus 15 hours for Sanger sequencing. Conclusion:The performance of PANDAA and Sanger population sequencing demonstrated complete concordance. PANDAA could improve patient management by providing quick and relatively cheap access to drug-resistance information.

8 October 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
IMIain J. MacLeod
Iain J. MacLeod
CRChristopher F. Rowley
Christopher F. Rowley
MEM. Essex
M. Essex
Global efforts to ensure that 90% of all HIV-infected people receiving antiretroviral therapy (ART) will be virally suppressed by 2020 could be crippled by increases in acquired and transmitted HIV drug resistance (HIVDR), which challenge ART efficacy. The long-term sustainability of ART treatment programs is contingent on effective HIVDR monitoring yet current Sanger sequencing genotypic resistance tests are inadequate for large-scale implementation in low- and middle-income countries (LMICs). A simple, rapid, affordable HIVDR diagnostic would radically improve the treatment paradigm in LMICs by facilitating informed clinical decision-making upon ART failure. Although point mutation assays can be broadly deployed in this context, the primary challenge arises from extensive sequence variation surrounding targeted drug resistance mutations (DRMs). Here, we systematically and intentionally violate the canonical principles of qPCR design to develop a novel assay, Pan-Degenerate Amplification and Adaptation (PANDAA), that mitigates the impact of DRM-proximal secondary polymorphisms on probe-based qPCR performance to enable subtype-independent, focused resistance genotyping. Using extremely degenerate primers with 3’ termini overlapping the probe-binding site, the HIV-1 genome is adapted through site-directed mutagenesis to replace secondary polymorphisms flanking the target DRM during the initial qPCR cycles. We show that PANDAA can quantify key HIV DRMs present at ≥5% and has diagnostic sensitivity and specificity of 96.9% and 97.5%, respectively, to detect DRMs associated with ART failure. PANDAA is an innovative solution for HIVDR genotyping and is an advancement in qPCR technology that could be applicable to any scenario where target-proximal genetic variability has been a roadblock in diagnostic development.

4 November 2026 in medRxiv
Verified
Preprint
Open access
PDF file
NANelson A. Adedosu
Nelson A. Adedosu
SASuleiman Y. Alhaji
Suleiman Y. Alhaji
JEJohnson Etafo
Johnson Etafo
IAIdris I. Abduljalail
Idris I. Abduljalail
RARuth I. Aderibigbe
Ruth I. Aderibigbe
IMIain J. MacLeod
Iain J. MacLeod
Background Lassa virus (LASV) intra- and inter-lineage nucleotide diversity has made it challenging to develop a single-reaction RT-PCR assay that can detect all viral variants with equal sensitivity. We evaluated PANDAA ® LASV, a single-reaction pan-lineage RT-PCR assay, at two Nigerian Lassa fever laboratories against the RealStar ® Lassa Virus RT-PCR Kit 2.0, the current diagnostic standard in Nigeria, which requires two separate reactions per patient sample to mitigate against false negative results. Methodology and Principal Findings We conducted a diagnostic accuracy study using retrospectively ( n = 200) and prospectively ( n = 100) plasma samples that had been collected from patients meeting the standard case definition of suspected Lassa fever for testing by real-time PCR at Abubakar Tafawa Balewa University Teaching Hospital in Bauchi and Federal Medical Centre in Owo. PANDAA LASV ® sensitivity was 98.6% (138/140; 95% CI 94.9–99.8%), specificity 99.4% (155/156; 96.5–100%), and accuracy 99.0% (293/296; 97.1–99.8%). The positive likelihood ratio was 153.8 (21.8–1084.9) and the negative likelihood ratio 0.01 (0.00–0.06). PANDAA Ct values correlated significantly with the reference assay L gene target (Spearman's ρ = 0.80; p < 0.0001) and GPC target (ρ = 0.69; p < 0.0001). Three confirmed discordant results occurred at high Ct values near assay detection limits. Performance was consistent across sites with overlapping confidence intervals for sensitivity and specificity and no difference in median Ct values for any assay target between laboratories. Ct values were significantly lower in patients ≥ 45 years ( p = 0.008). Conclusions and Significance PANDAA ® LASV demonstrated high diagnostic accuracy to detect Lassa virus RNA compared to the dual-reaction reference assay. Reducing the operational burden from two PCR reactions per sample to a single PANDAA ® LASV reaction while maintaining equivalent sensitivity and specificity could have a direct impact on labour and reagent costs, and turnaround time. Clinical validation against additional LASV lineages is an immediate priority.